<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Vet Intern Med</journal-id><journal-id journal-id-type="iso-abbrev">J. Vet. Intern. Med</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1939-1676</journal-id><journal-id journal-id-type="publisher-id">JVIM</journal-id><journal-title-group><journal-title>Journal of Veterinary Internal Medicine</journal-title></journal-title-group><issn pub-type="ppub">0891-6640</issn><issn pub-type="epub">1939-1676</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26290357</article-id><article-id pub-id-type="pmc">4858031</article-id><article-id pub-id-type="doi">10.1111/jvim.13588</article-id><article-id pub-id-type="publisher-id">JVIM13588</article-id><article-categories><subj-group subj-group-type="overline"><subject>Standard Article</subject></subj-group><subj-group subj-group-type="heading"><subject>SMALL ANIMAL</subject><subj-group subj-group-type="heading"><subject>Standard Articles</subject><subj-group subj-group-type="heading"><subject>Neurology</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Disposition of Extended Release Levetiracetam in Normal Healthy Dogs After Single Oral Dosing</article-title><alt-title alt-title-type="left-running-head">Beasley and Boothe</alt-title></title-group><contrib-group><contrib id="jvim13588-cr-0001" contrib-type="author" corresp="yes"><name><surname>Beasley</surname><given-names>M.J.</given-names></name><xref ref-type="aff" rid="jvim13588-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jvim13588-curr-0001">
<sup>3</sup>
</xref></contrib><contrib id="jvim13588-cr-0002" contrib-type="author"><name><surname>Boothe</surname><given-names>D.M.</given-names></name><xref ref-type="aff" rid="jvim13588-aff-0002">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="jvim13588-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Department of Clinical Sciences</named-content><institution>College of Veterinary Medicine</institution><institution>Auburn University</institution><named-content content-type="city">Auburn</named-content><named-content content-type="country-part">AL</named-content></aff><aff id="jvim13588-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Department of Clinical Pharmacology</named-content><institution>College of Veterinary Medicine</institution><institution>Auburn University</institution><named-content content-type="city">Auburn</named-content><named-content content-type="country-part">AL</named-content></aff><aff id="jvim13588-curr-0001"><label><sup>3</sup></label>Present address: <named-content content-type="organisation-division">Department of Clinical Sciences</named-content><institution>College of Veterinary Medicine</institution><institution>Mississippi State University</institution><named-content content-type="city">Mississippi State</named-content><named-content content-type="country-part">MS</named-content></aff><author-notes><corresp id="correspondenceTo"><label>*</label>Corresponding author: Dr M.J. Beasley, DVM, MS, ACVIM (Neurology), Department of Clinical Sciences, College of Veterinary Medicine, Mississippi State University, Mississippi State, MS 39762; e&#x02010;mail: <email>beasley@cvm.msstate.edu</email>.</corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2015</year></pub-date><volume>29</volume><issue>5</issue><issue-id pub-id-type="doi">10.1111/jvim.2015.29.issue-5</issue-id><fpage>1348</fpage><lpage>1353</lpage><history><date date-type="received"><day>08</day><month>7</month><year>2014</year></date><date date-type="rev-recd"><day>14</day><month>5</month><year>2015</year></date><date date-type="accepted"><day>25</day><month>6</month><year>2015</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2015 American College of Veterinary Internal Medicine <copyright-statement>--><copyright-statement content-type="article-copyright">Copyright &#x000a9; 2015 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of American College of Veterinary Internal Medicine.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x02010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JVIM-29-1348.pdf"/><abstract id="jvim13588-abs-0001"><sec id="jvim13588-sec-0001"><title>Background</title><p>Levetiracetam is an anticonvulsant used for control of canine epilepsy. An extended release preparation should improve dosing convenience.</p></sec><sec id="jvim13588-sec-0002"><title>Objectives</title><p>To determine the disposition of extended release levetiracetam in normal dogs after single dosing.</p></sec><sec id="jvim13588-sec-0003"><title>Animals</title><p>Pharmacokinetic study: 16 healthy, adult dogs.</p></sec><sec id="jvim13588-sec-0004"><title>Methods</title><p>Using a partially randomized crossover study, levetiracetam (30&#x000a0;mg/kg) was administered intravenously (<styled-content style="fixed-case">IV</styled-content>) and orally (<styled-content style="fixed-case">PO</styled-content>) as extended release preparation with or without food. Blood was collected for 24&#x000a0;hours (<styled-content style="fixed-case">IV</styled-content>) or 36&#x000a0;hours (<styled-content style="fixed-case">PO</styled-content>). Serum levetiracetam was quantitated by immunoassay and data were subjected to noncompartmental analysis.</p></sec><sec id="jvim13588-sec-0005"><title>Results</title><p>Pharmacokinetic parameters for fasted versus fed animals, respectively, were (mean&#x000a0;&#x000b1;&#x000a0;SEM): <italic>C</italic>
<sub>max</sub>&#x000a0;=&#x000a0;26.6&#x000a0;&#x000b1;&#x000a0;2.38 and 30.7&#x000a0;&#x000b1;&#x000a0;2.88&#x000a0;&#x003bc;/mL, <italic>T</italic>
<sub>max</sub>&#x000a0;=&#x000a0;204.3&#x000a0;&#x000b1;&#x000a0;18.9 and 393.8&#x000a0;&#x000b1;&#x000a0;36.6&#x000a0;minutes, <italic>t</italic>
<sub>1/2</sub>&#x000a0;=&#x000a0;4.95&#x000a0;&#x000b1;&#x000a0;0.55 and 4.48&#x000a0;&#x000b1;&#x000a0;0.48&#x000a0;hours, MRT&#x000a0;=&#x000a0;9.8&#x000a0;&#x000b1;&#x000a0;0.72 and 10&#x000a0;&#x000b1;&#x000a0;0.64&#x000a0;hours, MAT&#x000a0;=&#x000a0;4.7&#x000a0;&#x000b1;&#x000a0;0.38 and 5.6&#x000a0;&#x000b1;&#x000a0;0.67&#x000a0;hours, and <italic>F</italic>&#x000a0;=&#x000a0;1.04&#x000a0;&#x000b1;&#x000a0;0.04 and 1.26&#x000a0;&#x000b1;&#x000a0;0.07%. Significant differences were limited to <italic>T</italic>
<sub>max</sub> (longer) and <italic>F</italic> (greater) in fed compared to fasted animals. Serum levetiracetam concentration remained above 5&#x000a0;&#x003bc;/mL for approximately 20&#x000a0;hours in both fasted and fed animals.</p></sec><sec id="jvim13588-sec-0006"><title>Conclusions and Clinical Importance</title><p>Extended release levetiracetam (30&#x000a0;mg/kg q12h), with or without food, should maintain concentrations above the recommended minimum human therapeutic concentration.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jvim13588-kwd-0001">Anticonvulsants</kwd><kwd id="jvim13588-kwd-0002">Antiepileptics</kwd><kwd id="jvim13588-kwd-0003">Seizures</kwd></kwd-group><funding-group><award-group><funding-source>Morris Animal Foundation</funding-source></award-group></funding-group><counts><page-count count="6"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jvim13588</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September/October 2015</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.8.8 mode:remove_FC converted:25.04.2016</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="jvim13588-ntgp-0001"><fn id="jvim13588-note-0001"><p>This manuscript represents a portion of a thesis submitted by Dr Beasley to the Auburn University Department of Biomedical Sciences as partial fulfillment of the requirements for a Master of Science degree. Presented in abstract form at the 2012 ACVIM Forum, New Orleans, LA, June 2012 and in abstract form at the SEVEN Conference, Athens, GA, October 2011.</p></fn></fn-group></notes></front><body><def-list list-content="abbreviations" id="jvim13588-dl-0001"><title>Abbreviations</title><def-item><term>AR</term><def><p>accumulation ratio</p></def></def-item><def-item><term>AUC<sub>IV</sub></term><def><p>area under the curve for intravenous administration</p></def></def-item><def-item><term>AUC<sub>oral</sub></term><def><p>area under the curve for oral administration</p></def></def-item><def-item><term>Cl</term><def><p>clearance</p></def></def-item><def-item><term><italic>C</italic><sub>max</sub></term><def><p>maximum concentration</p></def></def-item><def-item><term><italic>C</italic><sub>o</sub></term><def><p>plasma drug concentration at time 0</p></def></def-item><def-item><term>Dose<sub>IV</sub></term><def><p>dose for intravenous administration</p></def></def-item><def-item><term>Dose<sub>oral</sub></term><def><p>dose for oral administration</p></def></def-item><def-item><term><italic>F</italic></term><def><p>bioavailability</p></def></def-item><def-item><term>Kel</term><def><p>elimination rate constant</p></def></def-item><def-item><term><italic>K</italic></term><def><p>terminal elimination rate constant</p></def></def-item><def-item><term>MAT</term><def><p>mean absorption time</p></def></def-item><def-item><term>MRT<sub>IV</sub></term><def><p>mean residence time for intravenous administration</p></def></def-item><def-item><term>MRT</term><def><p>mean residence time</p></def></def-item><def-item><term>MRT<sub>oral</sub></term><def><p>mean residence time for oral administration</p></def></def-item><def-item><term>SEM</term><def><p>standard error of the mean</p></def></def-item><def-item><term><italic>t</italic><sub>&#x000bd;</sub></term><def><p>half&#x02010;life</p></def></def-item><def-item><term>tau</term><def><p>dosing interval</p></def></def-item><def-item><term><italic>T</italic><sub>max</sub></term><def><p>time to maximum concentration</p></def></def-item><def-item><term><italic>V</italic><sub>d</sub></term><def><p>volume of distribution</p></def></def-item></def-list><p>Seizures are among the most common neurologic disorders affecting companion animals, and their control generally requires lifelong daily medication.<xref rid="jvim13588-bib-0001" ref-type="ref">1</xref>, <xref rid="jvim13588-bib-0002" ref-type="ref">2</xref>, <xref rid="jvim13588-bib-0003" ref-type="ref">3</xref> The life span of dogs with epilepsy is shorter than dogs without epilepsy; antiepileptic medication adverse effects or inadequate seizure control lead to an even shorter life span.<xref rid="jvim13588-bib-0004" ref-type="ref">4</xref> Although phenobarbital and bromide are common choices for long&#x02010;term seizure management in dogs, the failure rate for sole or combination treatment remains 15&#x02013;30%.<xref rid="jvim13588-bib-0005" ref-type="ref">5</xref>, <xref rid="jvim13588-bib-0006" ref-type="ref">6</xref>
</p><p>Levetiracetam is a new antiepileptic drug found to be both safe and effective in dogs.<xref rid="jvim13588-bib-0007" ref-type="ref">7</xref>, <xref rid="jvim13588-bib-0008" ref-type="ref">8</xref>, <xref rid="jvim13588-bib-0009" ref-type="ref">9</xref>, <xref rid="jvim13588-bib-0010" ref-type="ref">10</xref>, <xref rid="jvim13588-bib-0011" ref-type="ref">11</xref>, <xref rid="jvim13588-bib-0012" ref-type="ref">12</xref> Favorable characteristics include a unique mechanism of action<xref rid="jvim13588-bib-0013" ref-type="ref">13</xref> (binding to the synaptic vesicle protein 2A), minimal metabolism,<xref rid="jvim13588-bib-0014" ref-type="ref">14</xref> few documented drug&#x02010;drug interactions,<xref rid="jvim13588-bib-0015" ref-type="ref">15</xref> and multiple administration routes (IV, PO, IM, per rectum).<xref rid="jvim13588-bib-0007" ref-type="ref">7</xref>, <xref rid="jvim13588-bib-0008" ref-type="ref">8</xref>, <xref rid="jvim13588-bib-0009" ref-type="ref">9</xref>, <xref rid="jvim13588-bib-0010" ref-type="ref">10</xref>, <xref rid="jvim13588-bib-0011" ref-type="ref">11</xref>, <xref rid="jvim13588-bib-0012" ref-type="ref">12</xref>, <xref rid="jvim13588-bib-0013" ref-type="ref">13</xref>, <xref rid="jvim13588-bib-0014" ref-type="ref">14</xref>, <xref rid="jvim13588-bib-0015" ref-type="ref">15</xref>, <xref rid="jvim13588-bib-0016" ref-type="ref">16</xref> Currently, based on previous studies in dogs, an average 3&#x02010;hour half&#x02010;life requires 8&#x02010;hour dosing intervals. Furthermore, drug concentrations will fluctuate &#x0003e;75% during a dosing interval,<xref ref-type="fn" rid="jvim13588-note-0102">1</xref> which may contribute to poor seizure control. An extended release levetiracetam product approved for use in humans has lengthened the dosing interval from 12 to 24&#x000a0;hours in human epileptic patients.<xref rid="jvim13588-bib-0017" ref-type="ref">17</xref>, <xref rid="jvim13588-bib-0018" ref-type="ref">18</xref>, <xref rid="jvim13588-bib-0019" ref-type="ref">19</xref>, <xref rid="jvim13588-bib-0020" ref-type="ref">20</xref> However, previous studies have indicated that dosing regimens for slow or extended release products approved for use in humans cannot accurately be extrapolated to dogs.<xref rid="jvim13588-bib-0021" ref-type="ref">21</xref> This necessitates testing of extended release products intended for use in humans, in dogs, before their use in canine epileptic patients. Differences may reflect particle sizes allowed through the human versus canine pylorus and shorter gastrointestinal transit time in dogs.<xref rid="jvim13588-bib-0022" ref-type="ref">22</xref>, <xref rid="jvim13588-bib-0023" ref-type="ref">23</xref>
</p><p>The goal of this study was to describe the pharmacokinetic parameters of extended release levetiracetam<xref ref-type="fn" rid="jvim13588-note-0103">2</xref> in neurologically normal, healthy dogs after a single dose, to determine the effects of food on its disposition, and to establish a dosing interval, which would maintain serum levetiracetam concentrations above the minimum therapeutic concentration established in humans (5&#x000a0;&#x003bc;g/mL) throughout the proposed dosing protocol.</p><sec id="jvim13588-sec-0008"><title>Materials and Methods</title><sec id="jvim13588-sec-0009"><title>Experimental Protocol</title><p>Sixteen privately owned adult (age 1&#x02013;5&#x000a0;years) dogs weighing a minimum of 15&#x000a0;kg (average weight, 34&#x000a0;kg; range, 20.4&#x02013;50&#x000a0;kg) were volunteered for this study and were assessed to be apparently healthy based on normal physical and neurologic examination, CBC, serum biochemistry, and urinalysis. They were studied using a nonrandomized, crossover study (IV followed by PO), but dogs were randomized to be fasted or receive food with the PO dose. All procedures were approved by Auburn University's Institutional Animal Care and Use Committee (IACUC) and Clinical Research Review Committee (CRRC). Owners signed a client informed consent (CIC) form before their pet's participation in the study.</p><p>The current dosing protocol for regular release levetiracetam results in a total of 60&#x000a0;mg/kg/day administered. Therefore, in an initial pilot study using 4 dogs, half received 30&#x000a0;mg/kg in anticipation of a 12&#x02010;hour dosing interval, and half received 60&#x000a0;mg/kg in anticipation of a 24&#x02010;hour dosing interval, to determine the dosage that would be studied in the remaining dogs. Based on these first 4 animals, a dosage of 30&#x000a0;mg/kg was chosen for the remaining 12 dogs because the 60&#x000a0;mg/kg dosage caused sedation and did not offer an advantage in terms of duration because serum levetiracetam concentrations were below the low end of the therapeutic range at 24&#x000a0;hours.</p><p>All remaining 12 dogs received approximately 30&#x000a0;mg/kg of levetiracetam first as a single IV dose<xref ref-type="fn" rid="jvim13588-note-0104">3</xref> followed by PO extended release dose<xref ref-type="fn" rid="jvim13588-note-0103">2</xref> separated by approximately 26.3&#x000a0;hours (approximately 8.7 half&#x02010;lives). For each dog, the IV dose was given first to assure that the PO dose could be given without concern of residual levetiracetam, thus allowing the entire study for each animal (IV and PO dose) to be performed using a single IV catheterization. The IV dose was diluted 1&#x000a0;:&#x000a0;1 with 0.9% NaCl<xref ref-type="fn" rid="jvim13588-note-0105">4</xref> and administered over approximately 2&#x000a0;minutes. Dogs randomized to be administered their PO dose with food were fed their provided home diet immediately after PO administration of the tablet. Those randomized to be fasted were not fed for at least 12&#x000a0;hours before and 4&#x000a0;hours after manual PO administration and then fed their home diet. Immediately before the study, cephalic (for drug administration) and lateral saphenous (for blood sampling) catheters were placed using topical lidocaine/prilocaine anesthetic<xref ref-type="fn" rid="jvim13588-note-0006">5</xref> and manual restraint. The pilot study protocol differed only in that the dogs received IV doses of 20&#x000a0;mg/kg and PO doses of either 30 or 60&#x000a0;mg/kg instead of equal doses IV and PO (to the closest tablet size) of approximately 30&#x000a0;mg/kg.</p><p>Blood samples (3&#x000a0;mL) were collected immediately before and at 5, 10, 15, 20, 40, 60, 90, 120, 150, 180, 240, 300, 360, 480, 600, 720, and 1,440&#x000a0;minutes after IV and 15, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, 900, 1,080, 1,260, 1,440, 1,800, and 2,160&#x000a0;minutes after PO administration. Catheters were irrigated after collection with an equivalent volume of 0.9% NaCl and with heparinized saline (0.1&#x000a0;U/mL)<xref ref-type="fn" rid="jvim13588-note-0007">6</xref> when more than 4&#x000a0;hours lapsed among sample collections. Samples were placed in glass red top tubes.<xref ref-type="fn" rid="jvim13588-note-0008">7</xref> Based on the US prescribing information from UCB Pharmaceuticals, the tablets should not be &#x0201c;chewed, broken or crushed.&#x0201d;<xref rid="jvim13588-bib-0024" ref-type="ref">24</xref> Because of this, dogs were dosed to the nearest 30&#x000a0;mg/kg, with the actual mean dose being 32.67&#x000a0;mg/kg (range, 29.4&#x02013;35.7&#x000a0;mg/kg).</p><p>Each dog was visually monitored throughout the study period for evidence of adverse drug reactions. In addition, physical and neurologic examinations, CBC, serum biochemistry, and urinalysis were performed on each dog at the completion of the study to compare to the preadministration results.</p></sec><sec id="jvim13588-sec-0010"><title>Measurement of Serum Levetiracetam Concentration</title><p>After clotting at room temperature, samples were centrifuged for 10&#x000a0;minutes at 1,900&#x000a0;&#x000d7;&#x000a0;<italic>g</italic> within 2&#x000a0;hours of collection. Serum was harvested and frozen at &#x02212;20&#x000b0;C until analysis. At the time of sample analysis, serum samples were thawed at room temperature and then vortexed to assure homogeneity. Levetiracetam was detected and quantitated in canine serum by a Food and Drug Administration human&#x02010;approved immunoassay<xref ref-type="fn" rid="jvim13588-note-0009">8</xref> on a general chemistry analyzer,<xref ref-type="fn" rid="jvim13588-note-0010">9</xref> which is described elsewhere.<xref rid="jvim13588-bib-0025" ref-type="ref">25</xref> The system was validated in canine serum using pooled canine serum to which had been added known concentrations of levetiracetam. Subsequent analysis was based on the manufacturer's levetiracetam calibrator and control kits<xref ref-type="fn" rid="jvim13588-note-0011">10</xref> which were designed for human serum. The package insert for the assay indicates a lack of cross&#x02010;reactivity with the major metabolite (L057/PBA).<xref rid="jvim13588-bib-0026" ref-type="ref">26</xref> Furthermore, this metabolite represents only 2&#x02013;9% of the dose (based on urinary excretion) in dogs compared to 24% of the dose in adult humans.<xref rid="jvim13588-bib-0014" ref-type="ref">14</xref>, <xref rid="jvim13588-bib-0027" ref-type="ref">27</xref> The upper and lower limits of quantitation are 100&#x000a0;&#x003bc;g/mL and 2&#x000a0;&#x003bc;g/mL, respectively.<xref rid="jvim13588-bib-0026" ref-type="ref">26</xref> The coefficient of variation based on canine controls was &#x0003c;14% for the low and &#x0003c;7% for the high range control. After validation in canine serum, manufacturer's controls are the basis for quality assurance. These are characterized by CV&#x000a0;&#x02264;&#x000a0;10% for all controls.<xref ref-type="fn" rid="jvim13588-note-0102">1</xref>
</p></sec><sec id="jvim13588-sec-0011"><title>Data Analysis</title><p>Serum levetiracetam concentration versus time data was subjected to noncompartmental analysis<xref ref-type="fn" rid="jvim13588-note-0012">11</xref> with area under the curve (AUC) determined to infinity by the trapezoidal method. For IV administration, peak serum concentrations were extrapolated to the <italic>y</italic>&#x02010;intercept (<italic>C</italic>
<sub>0</sub>), whereas for PO administration, the actual maximum concentration (<italic>C</italic>
<sub>max</sub>) occurring at time to maximum concentration (<italic>T</italic>
<sub>max</sub>) was determined. In addition, mean residence time (MRT), elimination half&#x02010;life (<italic>t</italic>
<sub>1/2</sub>), disappearance rate constant (<italic>k</italic>
<sub>d</sub>), and, after IV administration, clearance (Cl) and volume of distribution (<italic>V</italic>
<sub>d</sub>) were determined. Mean absorption time (MAT) was determined for PO doses based on the equation: MAT&#x000a0;=&#x000a0;MRT<sub>oral</sub>&#x000a0;&#x02212;&#x000a0;MRT<sub>IV</sub>. Absolute bioavailability (F) of PO administered levetiracetam was determined from the following equation: (AUC<sub>PO</sub>&#x000a0;&#x000d7;&#x000a0;Dose<sub>IV</sub>)/(AUC<sub>IV</sub>&#x000a0;&#x000d7;&#x000a0;Dose<sub>PO</sub>). Data were included from the pilot study for <italic>t</italic>
<sub>1/2</sub>, <italic>k</italic>
<sub>d</sub>, <italic>V</italic>
<sub>d</sub>, Cl, MRT, and F because these variables are independent of the dose administered. Only data from the 12 main study dogs were used for <italic>C</italic>
<sub>max</sub>, <italic>T</italic>
<sub>max</sub>, <italic>C</italic>
<sub>o</sub>, AUC, and MAT because these variables are dependent on dose administered.</p><p>Pharmacokinetic data are reported as mean&#x000a0;&#x000b1;&#x000a0;SD as determined by use of commercially available software.<xref ref-type="fn" rid="jvim13588-note-0012">11</xref> A Student's <italic>t</italic>&#x02010;test was used to compare pharmacokinetic parameters obtained for PO administration with and without food and a paired <italic>t</italic>&#x02010;test was used to compare IV and PO data by commercially available software<xref ref-type="fn" rid="jvim13588-note-0013">12</xref> because the variances were found to be equal based on folded <italic>F</italic>&#x000a0;&#x0003e;&#x000a0;0.05. Values of <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;.05 were considered significant.</p></sec></sec><sec id="jvim13588-sec-0012"><title>Results</title><sec id="jvim13588-sec-0013"><title>Adverse Effects</title><p>All dogs in the pilot and main study appeared to tolerate all doses well. Adverse effects apparently, were limited to transient mild sedation after the 60&#x000a0;mg/kg PO extended release dose in the pilot study. A single dog in the pilot study vomited 22&#x000a0;hours after IV administration of levetiracetam (at 20&#x000a0;mg/kg), but continued the study without further problems. Clinicopathologic data (results of CBC, serum biochemistry, and urinalysis) obtained after administrations were within normal limits and no clinically relevant changes were seen when compared to preadministration results for all animals.</p></sec><sec id="jvim13588-sec-0014"><title>Pharmacokinetics</title><p>Table&#x000a0;<xref rid="jvim13588-tbl-0001" ref-type="table-wrap">1</xref> delineates serum pharmacokinetics (mean&#x000a0;&#x000b1;&#x000a0;SD) and <italic>P</italic> values comparing IV to PO administration and Table&#x000a0;<xref rid="jvim13588-tbl-0002" ref-type="table-wrap">2</xref> delineates serum pharmacokinetics (mean&#x000a0;&#x000b1;&#x000a0;SD) after PO administration with <italic>P</italic> values comparing fasted to fed administration. Mean serum concentrations remained &#x0003e;5&#x000a0;&#x003bc;g/mL for minimum of 9.5&#x000a0;hours after IV administration (Fig&#x000a0;<xref rid="jvim13588-fig-0001" ref-type="fig">1</xref>). For PO administration, serum levetiracetam achieved the minimum therapeutic concentration of 5&#x000a0;&#x003bc;g/mL by 100&#x000a0;minutes in fasted dogs and 200&#x000a0;minutes in fed dogs. At 12&#x000a0;hours, levetiracetam concentrations (&#x003bc;g/mL; mean&#x000a0;&#x000b1;&#x000a0;SD) were higher (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;.0001) after PO (n&#x000a0;=&#x000a0;12; 15.5&#x000a0;&#x000b1;&#x000a0;5.3) compared to IV (n&#x000a0;=&#x000a0;12; 5.5&#x000a0;&#x000b1;&#x000a0;2.2) administration. Within the PO group, concentrations at 12&#x000a0;hours were lower (<italic>P</italic>&#x000a0;=&#x000a0;.03) in fed (n&#x000a0;=&#x000a0;6; 12.3&#x000a0;&#x000b1;&#x000a0;3.1) compared to fasted animals (18.6&#x000a0;&#x000b1;&#x000a0;5.3) because of the delayed peak in serum concentrations after PO administration with food. Concentrations remained above the minimum therapeutic concentration for a mean of 19.8&#x000a0;hours (range, 15&#x02013;24.2&#x000a0;hours) in fasted animals and 20.7&#x000a0;hours (range, 16.7&#x02013;28.7&#x000a0;hours) in fed animals (Fig&#x000a0;<xref rid="jvim13588-fig-0001" ref-type="fig">1</xref>). Fluctuation in drug concentrations from the time at which peak (<italic>C</italic>
<sub>max</sub>) was measured (<italic>t</italic>
<sub>max</sub>) to 24&#x000a0;hours averaged 11.2&#x02010;fold (range, 5.3&#x02013;15.8) in fasted and 13.7&#x02010;fold (range, 5.3&#x02013;26.4) in fed animals after single dose administration. However, fluctuation was decreased to 2.4&#x02010;fold (range, 1.9&#x02013;3.2) in fasted and 1.8&#x02010;fold (range, 1.4&#x02013;2.7) in fed animals when measured to 12&#x000a0;hours. The accumulation ratio (AR) was calculated by the equation AR&#x000a0;=&#x000a0;1/(1&#x000a0;&#x02212;&#x000a0;e<sup>&#x02212;<italic>K</italic>&#x000a0;&#x000d7;&#x000a0;tau</sup>) for a 12&#x02010; and 24&#x02010;hour dosing interval. In fasted animals, the mean AR was 1.27 for 12&#x02010;hour and 1.05 for 24&#x02010;hour dosing intervals. In fed animals, the mean AR was 1.21 for 12&#x02010;hour and 1.04 for 24&#x02010;hour dosing intervals.</p><table-wrap id="jvim13588-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Pharmacokinetics of levetiracetam in serum after IV (mean&#x000a0;&#x000b1;&#x000a0;SD: 32.5&#x000a0;&#x000b1;&#x000a0;2.1) administration of as single dose of levetiracetam to dogs (n&#x000a0;=&#x000a0;12)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Variable</th><th align="center" valign="top" rowspan="1" colspan="1">Mean&#x000a0;&#x000b1;&#x000a0;SD</th><th align="center" valign="top" rowspan="1" colspan="1">95% Confidence Interval</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>P</italic> Value Versus PO Fasted</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>P</italic> Value Versus PO Fed</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Co/<italic>y</italic>&#x02010;intercept (&#x003bc;/mL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">70.0&#x000a0;&#x000b1;&#x000a0;9.3</td><td align="center" rowspan="1" colspan="1">65&#x02013;75</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>t</italic>
<sub>&#x000bd;</sub> (hours)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">4.0&#x000a0;&#x000b1;&#x000a0;1.4</td><td align="center" rowspan="1" colspan="1">3.3&#x02013;4.7</td><td align="center" rowspan="1" colspan="1">.065</td><td align="center" rowspan="1" colspan="1">.20</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>k</italic>
<sub>d</sub> (hours)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.16&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="center" rowspan="1" colspan="1">&#x02212;0.05 to 0.4</td><td align="center" rowspan="1" colspan="1">.31</td><td align="center" rowspan="1" colspan="1">.043*</td></tr><tr><td align="left" rowspan="1" colspan="1">MRT (hours)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">5.4&#x000a0;&#x000b1;&#x000a0;1.4</td><td align="center" rowspan="1" colspan="1">4.7&#x02013;6.1</td><td align="center" rowspan="1" colspan="1">&#x0003c;.001*</td><td align="center" rowspan="1" colspan="1">&#x0003c;.001*</td></tr><tr><td align="left" rowspan="1" colspan="1">AUC (&#x003bc;&#x000a0;&#x000d7;&#x000a0;h/mL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">306&#x000a0;&#x000b1;&#x000a0;79.4</td><td align="center" rowspan="1" colspan="1">262&#x02013;349</td><td align="center" rowspan="1" colspan="1">.038*</td><td align="center" rowspan="1" colspan="1">.017*</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>V</italic>
<sub>d</sub> (L/kg)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.6&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="center" rowspan="1" colspan="1">0.58&#x02013;0.66</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">CL (mL/kg/h)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">114&#x000a0;&#x000b1;&#x000a0;25.6</td><td align="center" rowspan="1" colspan="1">101&#x02013;126</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td></tr></tbody></table><table-wrap-foot><fn id="jvim13588-note-0002"><p>Data from 4 pilot animals receiving 20&#x000a0;mg/kg IV were included for <italic>t</italic>
<sub>1/2</sub>, <italic>k</italic>
<sub>d</sub>, MRT, <italic>V</italic>
<sub>d</sub>, and CL only (n&#x000a0;=&#x000a0;16). Variables marked with an (*) represent statistically significant differences between IV and fasted or fed groups.</p></fn><fn id="jvim13588-note-0003"><p>
<italic>t</italic>
<sub>1/2</sub>, disappearance half&#x02010;life; <italic>k</italic>
<sub>d</sub>, disappearance rate constant; MRT, mean residence time; AUC, area under the curve; <italic>V</italic>
<sub>d</sub>, apparent volume of distribution; CL, serum clearance.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><table-wrap id="jvim13588-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Pharmacokinetics of extended release levetiracetam in serum after PO (mean&#x000a0;&#x000b1;&#x000a0;SD: 32.67&#x000a0;&#x000b1;&#x000a0;2.35&#x000a0;mg/kg) administration of a single dose to dogs (n&#x000a0;=&#x000a0;12)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Parameter</th><th align="center" valign="top" rowspan="1" colspan="1">Mean&#x000a0;&#x000b1;&#x000a0;SD Fasted</th><th align="center" valign="top" rowspan="1" colspan="1">95% Confidence Interval</th><th align="center" valign="top" rowspan="1" colspan="1">Mean&#x000a0;&#x000b1;&#x000a0;SD Fed</th><th align="center" valign="top" rowspan="1" colspan="1">95% Confidence Intervals</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>P</italic> Values Fed Versus Fasted</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic>C</italic>
<sub>max</sub> (&#x003bc;/mL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">26.6&#x000a0;&#x000b1;&#x000a0;5.8</td><td align="char" char="&#x02013;" rowspan="1" colspan="1">21&#x02013;31</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">30.7&#x000a0;&#x000b1;&#x000a0;7.1</td><td align="char" char="&#x02013;" rowspan="1" colspan="1">25&#x02013;36</td><td align="char" char="." rowspan="1" colspan="1">.30</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>T</italic>
<sub>max</sub> (hours)*</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">3.4&#x000a0;&#x000b1;&#x000a0;0.8</td><td align="char" char="&#x02013;" rowspan="1" colspan="1">2.7&#x02013;4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">6.6&#x000a0;&#x000b1;&#x000a0;1.5</td><td align="char" char="&#x02013;" rowspan="1" colspan="1">5.4&#x02013;7.8</td><td align="char" char="." rowspan="1" colspan="1">.0010*</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>t</italic>
<sub>&#x000bd;</sub> (hours)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">4.4&#x000a0;&#x000b1;&#x000a0;2.1</td><td align="char" char="&#x02013;" rowspan="1" colspan="1">3.8&#x02013;6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">4.2&#x000a0;&#x000b1;&#x000a0;1.1</td><td align="char" char="&#x02013;" rowspan="1" colspan="1">3.5&#x02013;5.4</td><td align="char" char="." rowspan="1" colspan="1">.53</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>k</italic>
<sub>d</sub> (hours)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.16&#x000a0;&#x000b1;&#x000a0;0.04</td><td align="char" char="&#x02013;" rowspan="1" colspan="1">0.13&#x02013;0.18</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.17&#x000a0;&#x000b1;&#x000a0;0.03</td><td align="char" char="&#x02013;" rowspan="1" colspan="1">0.15&#x02013;0.19</td><td align="char" char="." rowspan="1" colspan="1">.72</td></tr><tr><td align="left" rowspan="1" colspan="1">MRT (hours)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">9.8&#x000a0;&#x000b1;&#x000a0;2.0</td><td align="char" char="&#x02013;" rowspan="1" colspan="1">8.4&#x02013;11</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">10.8&#x000a0;&#x000b1;&#x000a0;1.8</td><td align="char" char="&#x02013;" rowspan="1" colspan="1">9.5&#x02013;12</td><td align="char" char="." rowspan="1" colspan="1">.31</td></tr><tr><td align="left" rowspan="1" colspan="1">MAT (hours)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">4.7&#x000a0;&#x000b1;&#x000a0;0.9</td><td align="char" char="&#x02013;" rowspan="1" colspan="1">4&#x02013;5.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">5.6&#x000a0;&#x000b1;&#x000a0;1.7</td><td align="char" char="&#x02013;" rowspan="1" colspan="1">4.3&#x02013;6.9</td><td align="char" char="." rowspan="1" colspan="1">.31</td></tr><tr><td align="left" rowspan="1" colspan="1">AUC (&#x003bc;&#x000a0;&#x000d7;&#x000a0;h/mL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">335.4&#x000a0;&#x000b1;&#x000a0;74.3</td><td align="char" char="&#x02013;" rowspan="1" colspan="1">276&#x02013;393</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">393.4&#x000a0;&#x000b1;&#x000a0;138.3</td><td align="char" char="&#x02013;" rowspan="1" colspan="1">282&#x02013;503</td><td align="char" char="." rowspan="1" colspan="1">.39</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>F</italic> (%)*</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.0&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="char" char="&#x02013;" rowspan="1" colspan="1">0.96&#x02013;1.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.3&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="char" char="&#x02013;" rowspan="1" colspan="1">1.12&#x02013;1.39</td><td align="char" char="." rowspan="1" colspan="1">.02*</td></tr></tbody></table><table-wrap-foot><fn id="jvim13588-note-0004"><p>Data from 4 pilot animals were included for <italic>t</italic>
<sub>1/2</sub>, <italic>k</italic>
<sub>d</sub>; disappearance rate constant; MRT, <italic>F</italic> (n&#x000a0;=&#x000a0;16). Variables marked with an (*) represent statistically significant differences between fasted and fed groups.</p></fn><fn id="jvim13588-note-0005"><p>
<italic>C</italic>
<sub>max</sub>, maximum plasma drug concentration at time&#x000a0;=&#x000a0;<italic>t</italic>
<sub>max</sub>; <italic>t</italic>
<sub>1/2</sub>, disappearance half&#x02010;life; <italic>k</italic>
<sub>d</sub>, disappearance rate constant; MRT, mean residence time; MAT, mean absorption time; AUC, area under the curve; <italic>F</italic>, % bioavailability.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><fig fig-type="Figure" xml:lang="en" id="jvim13588-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Mean&#x000a0;&#x000b1;&#x000a0;SD serum levetiracetam concentrations (n&#x000a0;=&#x000a0;12) at various times after IV (black circle) administration of levetiracetam and oral fasted (white square; n&#x000a0;=&#x000a0;7) and oral fed (black square; n&#x000a0;=&#x000a0;7) administration of extended release levetiracetam (mean 32.67&#x000a0;mg/kg [range 29.4&#x02013;35.7&#x000a0;mg/kg]). Time of levetiracetam administration was designated as time 0.</p></caption><graphic id="nlm-graphic-1" xlink:href="JVIM-29-1348-g001"/></fig></sec><sec id="jvim13588-sec-0015"><title>Statistical Analysis</title><p>Statistically significant differences between fasted and fed groups included <italic>t</italic>
<sub>max</sub>, which was longer (<italic>P</italic>&#x000a0;=&#x000a0;.001) and <italic>F</italic>, which was greater (<italic>P</italic>&#x000a0;=&#x000a0;.02) in fed compared to fasted dogs (Table&#x000a0;<xref rid="jvim13588-tbl-0002" ref-type="table-wrap">2</xref>). When comparing IV data to PO fasted data, significant differences included MRT (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;.001) and AUC (<italic>P</italic>&#x000a0;=&#x000a0;0.038). When comparing IV data to PO fed data, significant differences included MRT (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;.001), AUC (<italic>P</italic>&#x000a0;=&#x000a0;.017) and <italic>k</italic>
<sub>d</sub> (<italic>P</italic>&#x000a0;=&#x000a0;.043). MRT was significantly longer (9.8&#x000a0;&#x000b1;&#x000a0;2.0 and 10.8&#x000a0;&#x000b1;&#x000a0;1.8&#x000a0;hours versus 5.4&#x000a0;&#x000b1;&#x000a0;1.4&#x000a0;hours [<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;.001]) and AUC significantly larger (335.4&#x000a0;&#x000b1;&#x000a0;74.3 and 393.4&#x000a0;&#x000b1;&#x000a0;138.3 versus 306.4&#x000a0;&#x000b1;&#x000a0;79.4&#x000a0;&#x003bc;&#x000a0;&#x000d7;&#x000a0;h/mL) in fasted and fed PO compared to IV. Elimination half&#x02010;life did not differ between IV and either fasted or fed PO.</p></sec></sec><sec id="jvim13588-sec-0016"><title>Discussion</title><p>According to the Food and Drug Administration Orange Book, at least 12 different extended release products are approved for use in humans and thus available for extra label veterinary use in dogs. Although each will have been demonstrated to be bioequivalent in humans, this assurance cannot be extrapolated to dogs because extended release preparations formulated for humans are not always slowly released in dogs.<xref rid="jvim13588-bib-0021" ref-type="ref">21</xref> Flip&#x02010;flop pharmacokinetics often are attributed to extended release preparations implying that the rate of absorption is slower than the rate of elimination causing them to occur simultaneously, which causes the rate of absorption to determine the slope of the decline rather than the rate of elimination. Although significant differences could not be demonstrated in either disappearance rate constants or half&#x02010;life between PO (nonfed) and IV administration (the former reflecting an extended release preparation), this may only be a reflection of small sample size. The terminal slope of the line (<italic>k</italic>
<sub>d</sub>) measured on log concentration versus time plots was significantly steeper with IV<xref ref-type="fn" rid="jvim13588-note-0104">3</xref> compared to PO extended release formulation<xref ref-type="fn" rid="jvim13588-note-0103">2</xref> when administered with food, but not when administered to a fasted animal, suggesting that the presence of food slowed absorption sufficiently to allow the extended release preparation to have a longer exposure in the animal. That PO slow release resulted in a longer exposure time is demonstrated by significant differences in MRT, which was longer after PO versus IV administration; as was AUC when compared to both PO administrations and IV administration. This observation is further supported by graphic representation of the data showing a longer time within therapeutic concentrations with the extended release product<xref ref-type="fn" rid="jvim13588-note-0103">2</xref> (Fig&#x000a0;<xref rid="jvim13588-fig-0001" ref-type="fig">1</xref>). This finding, however, does not support true pharmacokinetic flip&#x02010;flop principles, but may be clinically relevant to the prescriber of this medication in recommending the medication be given with food.</p><p>The serum concentrations of the extended release PO levetiracetam<xref ref-type="fn" rid="jvim13588-note-0103">2</xref> were &#x02264;5&#x000a0;&#x003bc;g/mL by 20.7&#x000a0;hours (range, 16.7&#x02013;28.7&#x000a0;hours) after administration with food and 19.8&#x000a0;hours (range, 15&#x02013;24.2&#x000a0;hours) after administration to a fasted dog. This finding resulted in a total time above minimum therapeutic concentration (in humans of 5&#x000a0;&#x003bc;g/mL) of 18.3&#x000a0;hours in fasted and 17.7&#x000a0;hours in fed animals, respectively. Therefore, this study demonstrates that extended release levetiracetam<xref ref-type="fn" rid="jvim13588-note-0103">2</xref> displays an extended pharmacologic profile in the dog compared to IV formulations. Food did not negatively impact or prohibit absorption; it only slowed the disposition of extended release levetiracetam in dogs, a finding consistent with pharmacokinetics in humans.<xref rid="jvim13588-bib-0017" ref-type="ref">17</xref> Food did increase the time to reach maximum concentrations, but at the estimated accumulation, this difference would not be clinically relevant.</p><p>Although this study did not compare extended release to PO regular release, a recent abstract<xref ref-type="fn" rid="jvim13588-note-0014">13</xref> did compare the 2 preparations in dogs (n&#x000a0;=&#x000a0;5) receiving 20&#x000a0;mg/kg levetiracetam PO over an 8&#x02010;hour period. The investigators found the absorption half&#x02010;life to be 7.75&#x02010;fold longer, the elimination half&#x02010;life 1.43&#x02010;fold longer, and the AUC 5&#x02010;fold greater for the extended compared to regular release tablets. The AUC for regular release was 44.8&#x000a0;&#x003bc;&#x000a0;&#x000d7;&#x000a0;h/mL and with extended release 230&#x000a0;&#x003bc;&#x000a0;&#x000d7;&#x000a0;h/mL. This AUC for regular release is short when compared to previously published data,<xref rid="jvim13588-bib-0007" ref-type="ref">7</xref>, <xref rid="jvim13588-bib-0009" ref-type="ref">9</xref>, <xref rid="jvim13588-bib-0010" ref-type="ref">10</xref>, <xref rid="jvim13588-bib-0011" ref-type="ref">11</xref>, <xref rid="jvim13588-bib-0012" ref-type="ref">12</xref>, <xref rid="jvim13588-bib-0014" ref-type="ref">14</xref>, <xref rid="jvim13588-bib-0015" ref-type="ref">15</xref> which may reflect the short sampling period.</p><p>On the basis of this study, we recommend the dosage of extended release levetiracetam<xref ref-type="fn" rid="jvim13588-note-0103">2</xref> to be 30&#x000a0;mg/kg q12h. An elimination half&#x02010;life of 4.5&#x02013;5&#x000a0;hours based on the pharmacokinetic study indicates that drug concentrations will fluctuate approximately 50&#x02013;80% during a 12&#x02010;hour dosing interval with this approach. Monitoring is recommended to determine the most appropriate dosing interval based on an individual's response to serum drug concentrations because the current study used the 5&#x000a0;&#x003bc;g/mL concentration extrapolated from human medicine. Based on this study, 3&#x02010;hour peak and just before the next dose trough sampling times are recommended.</p><p>The extended release profile of levetiracetam is a result of its formulation,<xref rid="jvim13588-bib-0024" ref-type="ref">24</xref> and chewing of the tablets by dogs could negate these properties. Because in&#x000a0;situ hydrolysis of levetiracetam (the major metabolic pathway) occurs in plasma, only serum, and neither plasma nor whole blood, should be used for therapeutic drug monitoring.<xref rid="jvim13588-bib-0028" ref-type="ref">28</xref> Furthermore, the results reported here are specific to the studied preparation<xref ref-type="fn" rid="jvim13588-note-0103">2</xref> and will not necessarily apply to other extended release levetiracetam products intended for human use. The patent held by UCB Pharmaceuticals expired in September 2011 and many generic extended release levetiracetam products have entered the market. Each of these medications must be tested in dogs (or by therapeutic monitoring in the patient) to ensure the same pharmacokinetic profile as the trade name medication tested in this study.</p><p>Future recommendations include prospective clinical trials to ensure the same efficacy and safety profile with extended release levetiracetam as seen with regular release levetiracetam in dogs.</p></sec></body><back><ack id="jvim13588-sec-0017"><title>Acknowledgments</title><p>The authors acknowledge Roy Harmon for assistance in the analysis of samples. This study was supported by a grant by the Morris Animal Foundation.</p><p>
<italic>Conflict of Interest Declaration</italic>: Authors disclose no conflict of interest.</p><p>
<italic>Off&#x02010;label Antimicrobial Declaration</italic>: The authors declare no off&#x02010;label use of antimicrobials.</p></ack><fn-group id="jvim13588-ntgp-0004"><title>Footnotes</title><fn id="jvim13588-note-0102"><label>1</label><p>Personal communication, Auburn University Clinical Pharmacology Laboratory</p></fn><fn id="jvim13588-note-0103"><label>2</label><p>Keppra XR, 500 and 750&#x000a0;mg tablets, UCB Pharmaceuticals, Brussels, Belgium</p></fn><fn id="jvim13588-note-0104"><label>3</label><p>Keppra, parental 100&#x000a0;mg/mL formulation, UCB Pharmaceuticals, Brussels, Belgium</p></fn><fn id="jvim13588-note-0105"><label>4</label><p>0.9% NaCl 1 Liter bags, Abbott Laboratories, Abbott Park, IL</p></fn><fn id="jvim13588-note-0006"><label>5</label><p>Lidocaine &#x00026; Prilocaine cream, 2.5%/2.5%, Fougera Pharmaceuticals, Melville, NY</p></fn><fn id="jvim13588-note-0007"><label>6</label><p>Heparin (1,000&#x000a0;U/mL), Sagent Pharmaceuticals Inc, Schaumburg, IL</p></fn><fn id="jvim13588-note-0008"><label>7</label><p>Kendall Monoject Blood Collection Tubes, 5&#x000a0;ml Red top, Kendall, Munsfield, Maine</p></fn><fn id="jvim13588-note-0009"><label>8</label><p>ARK Diagnostic Levetiracetam Immunoassay, Sunnyvale, CA</p></fn><fn id="jvim13588-note-0010"><label>9</label><p>Siemens Dimension Xpand Plus, New York, NY</p></fn><fn id="jvim13588-note-0011"><label>10</label><p>ARK Diagnostic Levetiracetam Calibrator Kit, Sunnyvale, CA</p></fn><fn id="jvim13588-note-0012"><label>11</label><p>WinNonLin Professional, version 4.1, Pharsight Corp, Mountain View, CA</p></fn><fn id="jvim13588-note-0013"><label>12</label><p>SAS for Windows, version 9.2, SAS Institute Inc, Cary, NC</p></fn><fn id="jvim13588-note-0014"><label>13</label><p>Platt SR, Kent M, Freeman AC, et&#x000a0;al. Pharmacokinetic evaluation of extended release levetiracetam in dogs. J Vet Intern Med 2011; 25(4): 729 (ACVIM abstracts)</p></fn></fn-group><ref-list content-type="cited-references" id="jvim13588-bibl-0001"><title>References</title><ref id="jvim13588-bib-0001"><label>1</label><mixed-citation publication-type="book" id="jvim13588-cit-0001">
<string-name>
<surname>Thomas</surname>
<given-names>WB</given-names>
</string-name>, <string-name>
<surname>Dewey</surname>
<given-names>CW</given-names>
</string-name>. <chapter-title>Seizures and narcolepsy</chapter-title> In: <person-group person-group-type="editor"><name><surname>Dewey</surname><given-names>CW</given-names></name></person-group>, ed. <source>A Practical Guide to Canine and Feline Neurology</source>, <edition>2nd ed</edition>
<publisher-loc>Ames, IA</publisher-loc>: <publisher-name>Wiley&#x02010;Blackwell Publishers</publisher-name>; <year>2008</year>:<fpage>237</fpage>&#x02013;<lpage>253</lpage>.</mixed-citation></ref><ref id="jvim13588-bib-0002"><label>2</label><mixed-citation publication-type="miscellaneous" id="jvim13588-cit-0002">
<collab collab-type="authors">International Veterinary Information Service website</collab>
. <article-title>Braund's clinical neurology in small animals: Localization, diagnosis and treatment</article-title>. Berendt M. Epilepsy. Available at: <ext-link ext-link-type="uri" xlink:href="http://ivis.org/advances/Vite/berendt/chapter_frm.asp?LA=1">http://ivis.org/advances/Vite/berendt/chapter_frm.asp?LA&#x0003d;1</ext-link>. Accessed November 10, 2013.</mixed-citation></ref><ref id="jvim13588-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jvim13588-cit-0003">
<string-name>
<surname>Zimmermann</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Hulsmeyer</surname>
<given-names>VI</given-names>
</string-name>, <string-name>
<surname>Sauter&#x02010;Louis</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Fischer</surname>
<given-names>A</given-names>
</string-name>. <article-title>Status epilepticus and epileptic seizures in dogs</article-title>. <source>J Vet Intern Med</source>
<year>2009</year>;<volume>23</volume>:<fpage>970</fpage>&#x02013;<lpage>976</lpage>.<pub-id pub-id-type="pmid">19737178</pub-id></mixed-citation></ref><ref id="jvim13588-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jvim13588-cit-0004">
<string-name>
<surname>Berendt</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gredal</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ersboll</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Alving</surname>
<given-names>J</given-names>
</string-name>. <article-title>Premature death, risk factors, and life patterns in dogs with epilepsy</article-title>. <source>J Vet Intern Med</source>
<year>2007</year>;<volume>21</volume>:<fpage>754</fpage>&#x02013;<lpage>759</lpage>.<pub-id pub-id-type="pmid">17708395</pub-id></mixed-citation></ref><ref id="jvim13588-bib-0005"><label>5</label><mixed-citation publication-type="book" id="jvim13588-cit-0005">
<string-name>
<surname>de Lahunta</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Glass</surname>
<given-names>EN</given-names>
</string-name>. <chapter-title>Seizure disorders: Narcolepsy</chapter-title> In: <person-group person-group-type="editor"><name><surname>de Lahunta</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>Glass</surname><given-names>EN</given-names></name></person-group>, eds. <source>Veterinary Neuroanatomy and Clinical Neurology</source>, <edition>3rd ed</edition>
<publisher-loc>St. Louis, MO</publisher-loc>: <publisher-name>Saunders Elsevier</publisher-name>; <year>2009</year>:<fpage>454</fpage>&#x02013;<lpage>468</lpage>.</mixed-citation></ref><ref id="jvim13588-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jvim13588-cit-0006">
<string-name>
<surname>Boothe</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Dewey</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Carpenter</surname>
<given-names>DM</given-names>
</string-name>. <article-title>Comparison of phenobarbital with bromide as a first&#x02010;choice antiepileptic drug for treatment of epilepsy in dogs</article-title>. <source>J Am Vet Med Assoc</source>
<year>2012</year>;<volume>240</volume>:<fpage>1073</fpage>&#x02013;<lpage>1083</lpage>.<pub-id pub-id-type="pmid">22515627</pub-id></mixed-citation></ref><ref id="jvim13588-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jvim13588-cit-0007">
<string-name>
<surname>Volk</surname>
<given-names>HA</given-names>
</string-name>, <string-name>
<surname>Matiasek</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Feliu&#x02010;Pascual</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Platt</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Chandler</surname>
<given-names>KE</given-names>
</string-name>. <article-title>The efficacy and tolerability of levetiracetam in pharmacoresistant epileptic dogs</article-title>. <source>Vet J</source>
<year>2008</year>;<volume>176</volume>:<fpage>310</fpage>&#x02013;<lpage>319</lpage>.<pub-id pub-id-type="pmid">17468024</pub-id></mixed-citation></ref><ref id="jvim13588-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jvim13588-cit-0008">
<string-name>
<surname>Thomas</surname>
<given-names>WB</given-names>
</string-name>. <article-title>Idiopathic epilepsy in dogs and cats</article-title>. <source>Vet Clin North Am Small Anim Pract</source>
<year>2010</year>;<volume>40</volume>:<fpage>161</fpage>&#x02013;<lpage>179</lpage>.<pub-id pub-id-type="pmid">19942062</pub-id></mixed-citation></ref><ref id="jvim13588-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jvim13588-cit-0009">
<string-name>
<surname>Patterson</surname>
<given-names>EE</given-names>
</string-name>, <string-name>
<surname>Goel</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Cloyd</surname>
<given-names>JC</given-names>
</string-name>, et&#x000a0;al. <article-title>Intramuscular, intravenous and oral levetiracetam in dogs: Safety and pharmacokinetics</article-title>. <source>J Vet Pharmacol Therap</source>
<year>2008</year>;<volume>31</volume>:<fpage>253</fpage>&#x02013;<lpage>258</lpage>.<pub-id pub-id-type="pmid">18471147</pub-id></mixed-citation></ref><ref id="jvim13588-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jvim13588-cit-0010">
<string-name>
<surname>Moore</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Munana</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>Papich</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Nettifee&#x02010;Osborne</surname>
<given-names>J</given-names>
</string-name>. <article-title>The pharmacokinetics of levetiracetam in healthy dogs following single and multiple oral doses</article-title>. <source>Am J Vet Res</source>
<year>2010</year>;<volume>71</volume>:<fpage>337</fpage>&#x02013;<lpage>341</lpage>.<pub-id pub-id-type="pmid">20187836</pub-id></mixed-citation></ref><ref id="jvim13588-bib-0011"><label>11</label><mixed-citation publication-type="miscellaneous" id="jvim13588-cit-0011">
<collab collab-type="authors">Veterinary Information Network website</collab>
, <string-name>
<surname>Steinberg</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Faissler</surname>
<given-names>D</given-names>
</string-name>. <article-title>Levetiracetam therapy for long&#x02010;term idiopathic epileptic dogs. ACVIM Oral Presentation 2004</article-title>. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.vin.com/Members/Proceedings/Proceedings.plx?CID&#x0003d;ACVIM2004%26PID=6247%26O=Generic">http://www.vin.com/Members/Proceedings/Proceedings.plx?CID&#x0003d;ACVIM2004&#x00026;PID&#x0003d;6247&#x00026;O&#x0003d;Generic</ext-link>. Accessed November 10, 2013.</mixed-citation></ref><ref id="jvim13588-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jvim13588-cit-0012">
<string-name>
<surname>Bailey</surname>
<given-names>KS</given-names>
</string-name>, <string-name>
<surname>Dewey</surname>
<given-names>CW</given-names>
</string-name>, <string-name>
<surname>Boothe</surname>
<given-names>DM</given-names>
</string-name>, et&#x000a0;al. <article-title>Pharmacokinetics of single&#x02010;dose intravenous levetiracetam administration in normal dogs</article-title>. <source>J Vet Emerg Crit Care</source>
<year>2008</year>;<volume>18</volume>:<fpage>153</fpage>&#x02013;<lpage>157</lpage>.</mixed-citation></ref><ref id="jvim13588-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jvim13588-cit-0013">
<string-name>
<surname>Lynch</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Lambeng</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Nocka</surname>
<given-names>K</given-names>
</string-name>, et&#x000a0;al. <article-title>The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2004</year>;<volume>101</volume>:<fpage>9861</fpage>&#x02013;<lpage>9866</lpage>.<pub-id pub-id-type="pmid">15210974</pub-id></mixed-citation></ref><ref id="jvim13588-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jvim13588-cit-0014">
<string-name>
<surname>Benedetti</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Coupez</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Whomsley</surname>
<given-names>R</given-names>
</string-name>, et&#x000a0;al. <article-title>Comparative pharmacokinetics and metabolism of levetiracetam, a new anti&#x02010;epileptic agent, in mouse, rat, rabbit and dogs</article-title>. <source>Xenobiotica</source>
<year>2004</year>;<volume>34</volume>:<fpage>281</fpage>&#x02013;<lpage>300</lpage>.<pub-id pub-id-type="pmid">15204700</pub-id></mixed-citation></ref><ref id="jvim13588-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jvim13588-cit-0015">
<string-name>
<surname>Moore</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Munana</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>Papich</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Nettifee&#x02010;Osborne</surname>
<given-names>JA</given-names>
</string-name>. <article-title>The pharmacokinetics of levetiracetam in healthy dogs concurrently receiving phenobarbital</article-title>. <source>J Vet Pharmacol Ther</source>
<year>2010</year>;<volume>34</volume>:<fpage>31</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">21219341</pub-id></mixed-citation></ref><ref id="jvim13588-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jvim13588-cit-0016">
<string-name>
<surname>Peters</surname>
<given-names>RK</given-names>
</string-name>, <string-name>
<surname>Schubert</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Clemmons</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Vickroy</surname>
<given-names>T</given-names>
</string-name>. <article-title>Levetiracetam rectal administration in healthy dogs</article-title>. <source>J Vet Int Med</source>
<year>2014</year>;<volume>28</volume>:<fpage>504</fpage>&#x02013;<lpage>509</lpage>.</mixed-citation></ref><ref id="jvim13588-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jvim13588-cit-0017">
<string-name>
<surname>Routis</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Burton</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Guenole</surname>
<given-names>E</given-names>
</string-name>, et&#x000a0;al. <article-title>Pharmacokinetics of levetiracetam XR 500&#x000a0;mg tablets</article-title>. <source>Epilepsy Res</source>
<year>2009</year>;<volume>84</volume>:<fpage>224</fpage>&#x02013;<lpage>231</lpage>.<pub-id pub-id-type="pmid">19264451</pub-id></mixed-citation></ref><ref id="jvim13588-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jvim13588-cit-0018">
<string-name>
<surname>Peltola</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Coetzee</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Jimenez</surname>
<given-names>F</given-names>
</string-name>, et&#x000a0;al. <article-title>Once&#x02010;daily extended&#x02010;release levetiracetam as adjunctive treatment of partial&#x02010;onset seizures in patients with epilepsy: A double&#x02010;blind, randomized, placebo&#x02010;controlled trail</article-title>. <source>Epilepsia</source>
<year>2009</year>;<volume>50</volume>:<fpage>406</fpage>&#x02013;<lpage>414</lpage>.<pub-id pub-id-type="pmid">19317886</pub-id></mixed-citation></ref><ref id="jvim13588-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jvim13588-cit-0019">
<string-name>
<surname>Richy</surname>
<given-names>FF</given-names>
</string-name>, <string-name>
<surname>Banerjee</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Brabant</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Helmers</surname>
<given-names>S</given-names>
</string-name>. <article-title>Levetiracetam extended release and levetiracetam immediate release as adjunctive treatment for partial&#x02010;onset seizures: An indirect comparison of treatment&#x02010;emergent adverse events using meta&#x02010;analytic techniques</article-title>. <source>Epilepsy Behav</source>
<year>2009</year>;<volume>16</volume>:<fpage>240</fpage>&#x02013;<lpage>245</lpage>.<pub-id pub-id-type="pmid">19699156</pub-id></mixed-citation></ref><ref id="jvim13588-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jvim13588-cit-0020">
<string-name>
<surname>Ulloa</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Towfigh</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Safdieh</surname>
<given-names>J</given-names>
</string-name>. <article-title>Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial&#x02010;onset seizures</article-title>. <source>Neuropsychiatr Dis Treat</source>
<year>2009</year>;<volume>5</volume>:<fpage>467</fpage>&#x02013;<lpage>476</lpage>.<pub-id pub-id-type="pmid">19777068</pub-id></mixed-citation></ref><ref id="jvim13588-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jvim13588-cit-0021">
<string-name>
<surname>Brown</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Forrester</surname>
<given-names>SD</given-names>
</string-name>. <article-title>Serum disposition of oral clorazepate from regular&#x02010;release and sustained&#x02010;delivery tablets in dogs</article-title>. <source>J Vet Pharmacol Ther</source>
<year>1991</year>;<volume>14</volume>:<fpage>426</fpage>&#x02013;<lpage>429</lpage>.<pub-id pub-id-type="pmid">1774820</pub-id></mixed-citation></ref><ref id="jvim13588-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jvim13588-cit-0022">
<string-name>
<surname>Martinez</surname>
<given-names>MN</given-names>
</string-name>, <string-name>
<surname>Papich</surname>
<given-names>MG</given-names>
</string-name>. <article-title>Factors influencing the gastric&#x000a0;residence of dosage forms in dogs</article-title>. <source>J Pharm Sci</source>
<year>2009</year>;<volume>98</volume>:<fpage>844</fpage>&#x02013;<lpage>860</lpage>.<pub-id pub-id-type="pmid">18661535</pub-id></mixed-citation></ref><ref id="jvim13588-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jvim13588-cit-0023">
<string-name>
<surname>Sutton</surname>
<given-names>SC</given-names>
</string-name>. <article-title>Companion animal physiology and dosage form performance</article-title>. <source>Adv Drug Deliv Rev</source>
<year>2004</year>;<volume>56</volume>:<fpage>1383</fpage>&#x02013;<lpage>1398</lpage>.<pub-id pub-id-type="pmid">15191788</pub-id></mixed-citation></ref><ref id="jvim13588-bib-0024"><label>24</label><mixed-citation publication-type="miscellaneous" id="jvim13588-cit-0024">
<collab collab-type="authors">UCB website</collab>
. <article-title>UCB US prescribing information Keppra<sup>&#x000ae;</sup> XR extended release tablets</article-title>. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.ucb.com/_up/ucb_com_products/documents/Keppra_XR_%2006_2012.pdf">http://www.ucb.com/_up/ucb_com_products/documents/Keppra_XR_%2006_2012.pdf</ext-link>. Accessed June 20, 2012.</mixed-citation></ref><ref id="jvim13588-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jvim13588-cit-0025">
<string-name>
<surname>Carnes</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Axlund</surname>
<given-names>TW</given-names>
</string-name>, <string-name>
<surname>Boothe</surname>
<given-names>DM</given-names>
</string-name>. <article-title>Pharmacokinetics of levetiracetam after oral and intravenous administration of a single dose to clinically normal cats</article-title>. <source>AJVR</source>
<year>2011</year>;<volume>72</volume>:<fpage>1247</fpage>&#x02013;<lpage>1252</lpage>.</mixed-citation></ref><ref id="jvim13588-bib-0026"><label>26</label><mixed-citation publication-type="miscellaneous" id="jvim13588-cit-0026">
<collab collab-type="authors">ARK website</collab>
. <article-title>ARK levetiracetam assay</article-title>. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.ark-tdm.com/pdfs/WEB_LEV/ARK_Levetiracetam_Control_Rev02_August%202012.pdf">http://www.ark-tdm.com/pdfs/WEB_LEV/ARK_Levetiracetam_Control_Rev02_August%202012.pdf</ext-link>. Accessed September 19, 2014.</mixed-citation></ref><ref id="jvim13588-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jvim13588-cit-0027">
<string-name>
<surname>Isoherranen</surname>
<given-names>N</given-names>
</string-name>, et&#x000a0;al. <article-title>Pharmacokinetics of levetiracetam and its enantiomer (R)&#x02010;&#x003b1;&#x02010;ethyl&#x02010;2&#x02010;oxo&#x02010;pyrrolidine acetamide in dogs</article-title>. <source>Epilepsia</source>
<year>2001</year>;<volume>42</volume>:<fpage>825</fpage>&#x02013;<lpage>830</lpage>.<pub-id pub-id-type="pmid">11488879</pub-id></mixed-citation></ref><ref id="jvim13588-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jvim13588-cit-0028">
<string-name>
<surname>Patsalos</surname>
<given-names>PN</given-names>
</string-name>, <string-name>
<surname>Ghattaura</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ratnaraj</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Sander</surname>
<given-names>JW</given-names>
</string-name>. <article-title>In situ metabolism of levetiracetam in blood of patients with epilepsy</article-title>. <source>Epilepsia</source>
<year>2006</year>;<volume>47</volume>:<fpage>1818</fpage>&#x02013;<lpage>1821</lpage>.<pub-id pub-id-type="pmid">17116020</pub-id></mixed-citation></ref></ref-list></back></article>